ASCO 2023 | EQUILIBRIUM: ibrutinib with temozolomide and radiation in nGBM

Manmeet Ahluwalia, MD, MBA, FASCO, Baptist Health South Florida, Miami, FL, gives an overview of the Phase I EQUILIBRIUM trial (NCT03535350) of ibrutinib, an oral BTK inhibitor, with temozolomide and radiation in patients with newly-diagnosed glioblastoma (nGBM). Addition of ibrutinib was found to be safe and well tolerated in patients, and an additional Phase II trial is planned. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.